Logo

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

Share this

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

Shots:

  • SpringWorks and Dana-Farber collaborated to evaluate nirogacestat with anti-B-cell maturation antigen (BCMA) agents in multiple preclinical multiple myeloma models
  • SpringWorks will fund the work and will retain an option to exclusively license any new IP emerging from the research collaboration
  • The collaboration will utilize preclinical in vivo models from the Mitsiades Lab to simulate the MM tumor microenvironment. The research will deploy functional genomics approaches to explore determinants of response and mechanisms of resistance to GSI + BCMA combination therapy

  | Ref: Globe Newswire | Image: Neurofibromatosis Network

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions